Live Analyst Rating Changes 1641 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Julien Blouin
GS
Julien Blouin
Goldman Sachs
Wall Street Analyst
★★☆☆☆
#1883
on 13Foresight · ranked by our own returns
32%
Success Rate
-1.7%
Average Return
9 of 28 calls profitable · -6.3% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 32% of Julien Blouin's ratings turned a profit when each position was held for 1 year — averaging -1.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

24 Buy 18 Hold 10 Sell
Julien's Stock Coverage 19 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
INVH
Invitation Homes
 Jun 16, 2026 BUY Buy
+24.7% avg upside
34 analysts
$32.00
12.55% Upside
 -1.8%
UDR
UDR
 Jun 16, 2026 SELL Buy
+17.7% avg upside
31 analysts
$36.00
4.16% Downside
 ·
ESS
Essex Property
 Jun 16, 2026 HOLD Buy
+1.6% avg upside
33 analysts
$288.00
5.16% Upside
 -2.2%
MAA
Mid-America Apartment
 Jun 16, 2026 HOLD Buy
+12.7% avg upside
36 analysts
$132.00
0.35% Downside
 -2.9%
AMH
American Homes
 Jun 16, 2026 HOLD Strong Buy
+15.6% avg upside
31 analysts
$35.00
10.33% Upside
 ·
CPT
Camden Property
 Jun 16, 2026 SELL Buy
+8.7% avg upside
30 analysts
$102.00
6.38% Downside
 +3.0%
CBRE
CBRE Group
 Jun 10, 2026 BUY Strong Buy
+5.3% avg upside
23 analysts
$183.00
39.02% Upside
 -1.9%
CWK
Cushman & Wakefield
 Jun 04, 2026 BUY Buy
+26.9% avg upside
17 analysts
$17.00
31.78% Upside
 ·
NHP
National Healthcare Properties
 Jun 04, 2026 BUY Buy
+18.3% avg upside
8 analysts
$20.00
39.22% Upside
 ·
JAN
Janus Living, Inc. Class A
 Jun 03, 2026 HOLD Strong Buy
+10.2% avg upside
11 analysts
$28.00
6.71% Upside
 ·
VTR
Ventas
 Jun 03, 2026 BUY Strong Buy
+0.3% avg upside
34 analysts
$110.00
34.75% Upside
 +5.6%
OHI
Omega Healthcare
 Jun 02, 2026 BUY Buy
-3.6% avg upside
29 analysts
$63.00
41.40% Upside
 -0.4%
MRP
Millrose Properties Inc Class A
 May 28, 2026 BUY Strong Buy
+30.3% avg upside
6 analysts
$35.00
23.30% Upside
 ·
ARE
Alexandria Equities
 May 19, 2026 HOLD Buy
+44.4% avg upside
26 analysts
$52.00
1.90% Upside
 +7.3%
NMRK
Newmark Group
 May 04, 2026 BUY Strong Buy
+27.5% avg upside
12 analysts
$20.00
34.47% Upside
 -6.7%
JLL
Jones Lang Lasalle
 May 04, 2026 BUY Buy
-1.1% avg upside
17 analysts
$417.00
40.18% Upside
 -5.2%
TSE:CIGI
Colliers International Group
 Feb 27, 2026 HOLD Strong Buy
+62.3% avg upside
15 analysts
$192.62
48.27% Upside
 ·
DOC
Healthpeak Properties
 Jan 09, 2026 HOLD Buy
+17.8% avg upside
42 analysts
$17.00
13.18% Downside
 +20.1%
EQR
Equity Residential
 Sep 04, 2024 HOLD Buy
+13.7% avg upside
36 analysts
$81.00
26.44% Upside
 -9.7%
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Julien Blouin — Frequently Asked Questions
How accurate are Julien Blouin's stock ratings?
Based on the calls 13Foresight could measure, about 32% of Julien's ratings were profitable over a one-year hold, with an average return of -1.7% per rating, or -6.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Julien ranked on 13Foresight?
Julien Blouin is currently ranked #1883 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Julien cover?
Julien most recently has ratings on INVH, UDR, ESS, MAA, AMH, CPT, CBRE, CWK, NHP, JAN, VTR, OHI and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.